Special Issue

SARS-CoV-2 Research in Belgium

Message from the Guest Editors

Following the initial detection of the first COVID-19 infection in Belgium on February 3, 2020, Belgian research groups initiated a wide panel of research initiatives targeting different aspects of the SARS-CoV-2 pandemic. In this Special Issue, we aim to collect and synergise a wide variety of high-quality research efforts on SARS-CoV-2 in Belgium. Because the pandemic and its consequences on the health system and society in general outpaces the traditional scope of virology research, we aim to stimulate outstanding virology research, but also research papers which have taken a multidisciplinary approach to complex problems. Manuscripts covering the analysis of the different waves of the pandemic that hit Belgium and localised outbreaks in nursing homes, hospitals, the work sector and schools will be analysed with a great deal of attention, together with studies on phylogenetic and phylodynamic inference, outbreak and transmission chain analysis, clinical studies assessing the impact of novel diagnostic or treatment approaches, nextgeneration sequencing efforts, mathematical and epidemiological model development, vaccine efficacy, and intervention strategies.

Guest Editors

Dr. Guy Baele

Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium

Dr. Emmanuel André

KU Leuven, Laboratory of Clinical Bacteriology and Mycology, campus Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium

Deadline for manuscript submissions

closed (31 August 2022)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/102764

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

